Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 15, 2021 - Issue
Submit an article Journal homepage
453
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects

Lei Sheng1 Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-5784-076X
ORCID Icon,
Wei Cao2 Shanghai Rixin Biotechnology Co., Ltd, Shanghai, 200237, People’s Republic of China
,
Pingping Lin3 Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University, Shandong, 266071, People’s Republic of China
,
Weili Chen1 Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China
,
Hongrong Xu1 Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China
,
Chunjiu Zhong4 Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China
,
Fei Yuan1 Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China
,
Hanjing Chen1 Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-2136-2807
ORCID Icon,
Hui Li1 Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China
,
Chao Liu1 Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-5410-5519
ORCID Icon,
Mengjie Yang1 Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of China
&
Xuening Li1 Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 1101-1110 | Published online: 09 Mar 2021

References

  • SwerdlowRH. Pathogenesis of Alzheimer’s disease. Clin Interv Aging. 2007;2(3):347.18044185
  • RygielK. Novel strategies for Alzheimer’s disease treatment: an overview of anti-amyloid beta monoclonal antibodies. Indian J Pharmacol. 2016;48(6):629–636. doi:10.4103/0253-7613.19486728066098
  • HonigLS, VellasB, WoodwardM, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med. 2018;387(4):321–330. doi:10.1056/NEJMoa170597129365294
  • CummingsJ. Lessons learned from Alzheimer disease: clinical trials with negative outcomes. Clin Transl Sci. 2018;11(2):147–152. doi:10.1111/cts.1249128767185
  • BachurinSO, BovinaEV, UstyugovAA. Drugs in clinical trials for Alzheimer’s disease: the major trends. Med Res Rev. 2017;37(5):1186–1225. doi:10.1002/med.2143428084618
  • BalakumarP, RohillaA, KrishanP, SolairajP, ThangathirupathiA. The multifaceted therapeutic potential of benfotiamine. Pharmacol Res. 2010;61(6):482–488. doi:10.1016/j.phrs.2010.02.00820188835
  • VolvertML, SeyenS, PietteM, et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol. 2008;8(1):10. doi:10.1186/1471-2210-8-1018549472
  • SchreebKH, FreudenthalerS, VormfeldeSV, Gundert-RemyU, GleiterCH. Comparative bioavailability of two vitamin B1 preparations: benfotiamine and thiamine mononitrate. Eur J Clin Pharmacol. 1997;52(4):319–320.9248773
  • GrebA, BitschR. Comparative bioavailability of various thiamine derivatives after oral administration. Int J Clin Pharmacol Ther. 1998;36(4):216–221.9587048
  • HammesHP, DuX, EdelsteinD, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003;9(3):294–299. doi:10.1038/nm83412592403
  • VarkonyiT, PutzZ, KeresztesK, et al. Current options and perspectives in the treatment of diabetic neuropathy. Curr Pharm Des. 2013;19(27):4981–5007. doi:10.2174/1381612811319999031023278494
  • NikolicA, KacarA, LavrnicD, BastaI, ApostolskiS. The effect of benfothiamine in the therapy of diabetic polyneuropathy. Srp Arh Celok Lek. 2009;137(11–12):594–600. doi:10.2298/SARH0912594N20069914
  • NacitarhanC, MinareciE, SadanG. The effect of benfotiamine on mu-opioid receptor mediated antinociception in experimental diabetes. Exp Clin Endocrinol Diabetes. 2014;122(3):173–178. doi:10.1055/s-0033-136397724643695
  • Ceylan-IsikAF, WuS, LiQ, LiSY, RenJ. High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitus. J Appl Physiol (1985). 2006;100(1):150–156. doi:10.1152/japplphysiol.00988.200516166234
  • PanX, GongN, ZhaoJ, et al. Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain. 2010;133(5):1342–1351. doi:10.1093/brain/awq06920385653
  • SunXJ, ZhaoL, ZhaoN, et al. Benfotiamine prevents increased beta-amyloid production in HEK cells induced by high glucose. Neurosci Bull. 2012;28(5):561–566. doi:10.1007/s12264-012-1264-022961478
  • TapiasV, JainuddinS, AhujaM, et al. Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy. Hum Mol Genet. 2018;27(16):2874–2892. doi:10.1093/hmg/ddy20129860433
  • PanX, ChenZ, FeiG, et al. Long-term cognitive improvement after benfotiamine administration in patients with Alzheimer’s disease. Neurosci Bull. 2016;32(6):591–596. doi:10.1007/s12264-016-0067-027696179
  • GibsonGE, LuchsingerJA, CirioR, et al. Benfotiamine and cognitive decline in Alzheimer’s disease: results of a randomized placebo-controlled Phase IIa clinical trial. J Alzheimers Dis. 2020;78(3):989–1010. doi:10.3233/JAD-20089633074237
  • ParkWS, LeeJ, HongT, et al. Comparative pharmacokinetic analysis of thiamine and its phosphorylated metabolites administered as multivitamin preparations. Clin Ther. 2016;38(10):2277–2285. doi:10.1016/j.clinthera.2016.08.00927707509
  • XieF, ChengZ, LiS, et al. Pharmacokinetic study of benfotiamine and the bioavailability assessment compared to thiamine hydrochloride. J Clin Pharmacol. 2014;54(6):688–695. doi:10.1002/jcph.26124399744

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.